Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Abroad (travel likely)RecruitingPHASE2

Conditions

Colorectal Cancer · KRAS G12C Mutant Advanced Solid Tumors · Fulzerasib · Cetuximab N01

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Kefeng Ding, PhD) · dingkefeng@zju.edu.cn · 86-571-87784827
Contact: Principal Investigator (Kefeng Ding, PhD)

Study leads

Kefeng Ding, PhD
Principal Investigator
Second Affiliated Hospital, Zhejiang University School of Medicine

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Solid Tumor · Non-Small-Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1

Santa Monica, United States · Atlanta, United States

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Rectal Cancer · Radiotherapy

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Colorectal Cancer Metastatic · Liver Metastases · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

New York, United States

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Colorectal Cancer Metastatic

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Newport Beach, United States